GTBP GT Biopharma, Inc.

Nasdaq gtbiopharma.com


$ 0.68 $ 0.00 (0 %)    

Friday, 17-Oct-2025 05:20:01 EDT
QQQ $ 592.68 $ 0.00 (0 %)
DIA $ 456.56 $ 0.00 (0 %)
SPY $ 654.22 $ 0.00 (0 %)
TLT $ 91.48 $ 0.00 (0 %)
GLD $ 399.06 $ 0.00 (0 %)
$ 0.682
$ 0.73
$ 0.68 x 150
$ 0.74 x 2
-- - --
$ 0.55 - $ 4.10
699,038
na
2.43M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 02-21-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 10-31-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-23-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 04-16-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 04-28-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-10-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-q2-eps-055-beats-068-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) ...

 gt-biopharma-initiated-dosing-in-cohort-3-of-its-phase-1-dose-escalation-trial-of-gtb-3650-for-relapsed-or-refractory-cd33-expressing-hematologic-malignancies-plans-on-releasing-initial-phase-1-results-later-in-2025-following-completion-of-additional-dose-cohorts

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful...

 gt-biopharma-q1-eps-033-beats-064-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) ...

 gt-biopharma-appoints-michael-breen-as-ceo-for-two-year-term

-SEC Filing

 gt-biopharma-doses-initial-patient-in-phase-1-trial-of-gtb-3650-next-generation-trike-for-hematologic-cancer-treatment

"We are thrilled to initiate patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with h...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION